<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>DRUG STUDY by Aaron Chris Sese</title>
      <link>https://padlet.com/seseaaronchris/q15jx0cv53onlw9v</link>
      <description></description>
      <language>en-us</language>
      <pubDate>2021-09-13 08:20:40 UTC</pubDate>
      <lastBuildDate>2021-09-14 23:19:09 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url>https://padlet.net/icons/png/1f48a.png</url>
      </image>
      <item>
         <title>DOPAMINE</title>
         <author>seseaaronchris</author>
         <link>https://padlet.com/seseaaronchris/q15jx0cv53onlw9v/wish/1735427249</link>
         <description><![CDATA[<div><strong>1. Generic Name</strong>: Dopamine Hydrochloride<br><br></div><div>&nbsp;<strong>2. Brand Name:</strong> Dopastat, Introstat, Revimine<br><br></div><div>&nbsp;<strong>3. Stock Dosage:&nbsp;</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Injection - 40 mg/mL, 80 mg/mL, 160 mg/mL injection<br><br></div><div><strong>4. Classification</strong>: Autonomic Nervous System Agent, Alpha- and Beta-Adrenergic Agonist (Sympathomimetic)<br><br><strong>5. Mechanism of Action: </strong>Naturally occurring neurotransmitter and immediate precursor of norepinephrine. Major cardiovascular effects produced by direct action on alpha- and beta-adrenergic receptors and on specific dopaminergic receptors in mesenteric and renal vascular beds.<br><strong><br> 6. Indication/s:</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Correction of hemodynamic balance in shock syndrome due to myocardial infarction</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Trauma</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Endotoxic Septicemia (septic shock)&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Open Heart Surgery</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Chronic Heart Failure&nbsp;</div><div><br>&nbsp;<strong>7. Contraindications</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Pheochromocytoma</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Tachyarrhythmias&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Ventricular Fibrillation</div><div><br>&nbsp;<strong>8. Side Effects and Adverse Effects</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>CV</strong>: Hypotension, ectopic beats, tachycardia, anginal pain, palpitation, vasoconstriction, cold extremities, bradycardia, , elevated blood pressure.&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>GI</strong>: Nausea, vomiting.</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>CNS</strong>: Headache.&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Skin</strong>: Necrosis, tissue sloughing with extravasation, gangrene.</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Other</strong>: Azotemia, dyspnea, dilated pupils (high doses).</div><div><br>&nbsp;<strong>9. Nursing Responsibilities</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Monitor blood pressure, pulse, peripheral pulses, and urinary output.&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Monitor therapeutic effectiveness.</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Report the following indicators promptly to physician: Reduced urine flow rate in absence of hypotension; ascending tachycardia; dysrhythmias; disproportionate rise in diastolic pressure (marked decrease in pulse pressure); signs of peripheral ischemia (pallor, cyanosis, mottling, coldness, complaints of tenderness, pain, numbness, or burning sensation).</div><div>&nbsp;<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2021-09-13 08:26:33 UTC</pubDate>
         <guid>https://padlet.com/seseaaronchris/q15jx0cv53onlw9v/wish/1735427249</guid>
      </item>
      <item>
         <title>Atorvastatin </title>
         <author>seseaaronchris</author>
         <link>https://padlet.com/seseaaronchris/q15jx0cv53onlw9v/wish/1735442985</link>
         <description><![CDATA[<div><strong>1. Generic Name:</strong> Atorvastatin Calcium<br><br><strong>2. Brand Name:</strong> Lipitor <br><br><strong>3. Stock Dosage:</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Tablets: 10 mg, 20 mg, 40 mg<br><br></div><div>&nbsp;<strong>4. Classification:</strong> Cardiovascular Agent, Antilipemic Agnet, HMG-COA; Reductase Inhibitor (Statin)<br><br></div><div><strong>5. Mechanism of Action:</strong> Atorvastatin is an inhibitor of reductase 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA), which is essential to hepatic production of cholesterol. Lipitor increases the number of hepatic low-density-lipid (LDL) receptors, thus increasing LDL uptake and catabolism of LDL.<br><br></div><div><strong>6. Indication/s&nbsp;</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Adjunct to diet for the reduction of LDL cholesterol and triglycerides in patients with primary hypercholesterolemia and mixed dyslipidemia.<br>&nbsp;</div><div><strong>7. Contraindications</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hypersensitivity to atorvastatin</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Myopathy</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Active Liver Disease</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Unexplained Persistent Transaminase Elevations&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Pregnancy (category X)</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Lactation<br>&nbsp;</div><div><strong>8. Side Effects and Adverse Effects</strong></div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Body as a Whole:</strong> Back pain, asthenia, hypersensitivity reaction, myalgia, rhabdomyolysis&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>CNS:</strong> Headache</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>GI:</strong> Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, increased liver function tests&nbsp;</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Respiratory:</strong> Sinusitis, pharyngitis</div><div>·&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong>Skin:</strong> Rash<br>&nbsp;</div><div><strong>9. Nursing Responsibilities</strong></div><ul><li>Monitor for therapeutic effectiveness which is indicated by reduction in the level of LDL-C.</li><li>Lab tests: Monitor lipid levels within 2–4 weeks after initiation of therapy or upon change in dosage; monitor liver functions at 6 and 12 weeks after initiation or elevation of dose, and periodically thereafter.</li><li>Assess for muscle pain, tenderness, or weakness; and, if present, monitor CPK level (discontinue drug with marked elevations of CPK or if myopathy is suspected).</li><li>Monitor carefully for digoxin toxicity with concurrent digoxin use.</li><li>Instruct patient to Report promptly any of the following: Unexplained muscle pain, tenderness, or weakness, especially with fever or malaise; yellowing of skin or eyes; stomach pain with nausea, vomiting, or loss of appetite; skin rash or hives.</li><li>Instruct not to take drug during pregnancy because it may cause birth defects. Immediately inform physician of a suspected or known pregnancy.</li><li>Instruct patient to not breast feed while taking this drug.</li></ul>]]></description>
         <enclosure url="" />
         <pubDate>2021-09-13 08:34:39 UTC</pubDate>
         <guid>https://padlet.com/seseaaronchris/q15jx0cv53onlw9v/wish/1735442985</guid>
      </item>
   </channel>
</rss>
